Category - Developments

Developments

SELLAS reports positive follow-up data from Phase 1/2 acute myeloid leukemia trial

SELLAS Life Sciences (NASDAQ:SLS) reported final follow-up data from its Phase 1/2 study of galinpepimut-S in patients with acute myeloid leukemia (AML) in second complete remission. The data demonstrate a median...

February 26, 2020

Developments

Oramed posts positive results in final cohort of Phase 2b oral insulin trial

Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) reported positive topline data from the second and final cohort of its Phase 2b trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801, at lower...

February 26, 2020

Developments

Kane Biotech launches anti-biofilm shampoo at the Global Pet Expo

Kane Biotech (TSX-V:KNE) launched its silkstem anti-itch shampoo at the Global Pet Expo taking place on February 26-28, 2020 in Orlando, Florida. silkstem is a scientifically formulated anti-itch shampoo for dogs and...

February 26, 2020

Developments

Kane Biotech signs first U.S. distribution agreement with King Wholesale

Kane Biotech (TSXV:KNE) signed an agreement with King Wholesale, a California-based distributor of wholesale pet supplies. Under the accord, King will distribute Kane’s bluestem oral care and silkstem anti-itch shampoo...

February 25, 2020

Developments

FDA approves Baudax Bio’s ANJESO for pain

The FDA approved Baudax Bio’s (NASDAQ:BXRX) ANJESO for the management of moderate-to-severe pain, alone or in combination with other non-NSAID analgesics. ANJESO is a once-daily COX-2 preferential NSAID that is...

February 21, 2020

Developments

VBL Therapeutics launches Phase 2 metastatic colorectal cancer trial

VBL Therapeutics (NASDAQ:VBLT) launched a Phase 2 trial evaluating VB-111, in combination with nivolumab, for the treatment of metastatic colorectal cancer. VB-111, an adenovirus that carries a transgene for the Fas...

February 20, 2020

Developments

VistaGen reports positive results from Phase 2a major depressive disorder study

VistaGen Therapeutics (NASDAQ:VTGN) reported positive results from its Phase 2a clinical study of PH10 for treatment of major depressive disorder (MDD). PH10 is a synthetic neurosteroid nasal spray designed to activate...

February 20, 2020

Developments

Mesoblast moving remestemcel-L into chronic GVHD pivotal trial

Mesoblast (NASDAQ:MESO; ASX:MSB) achieved clinically meaningful outcomes in all three treated patients, two children and one adult, within 28 days after two infusions of its allogeneic cell therapy product candidate...

February 20, 2020

Developments

Obalon opens second retail treatment center to treat obesity

Obalon Therapeutics (NASDAQ:OBLN) opened its second company-managed retail center in Orange County, Calif. to treat obesity with its swallowable, gas-filled intragastric balloon system. In a statement, Bill Plovanic...

February 20, 2020

Developments

Hepion’s CRV431 shows potential to impact multiple types of fibrotic disease

Hepion Pharmaceuticals (NASDAQ:HEPA) reported results from in vitro studies showing that CRV431 can decrease production of the extracellular matrix (ECM) molecules, collagen and fibronectin, from fibroblastic cells. The...

February 19, 2020

Category - Developments

SELLAS reports positive follow-up data from Phase 1/2 acute myeloid leukemia trial

Oramed posts positive results in final cohort of Phase 2b oral insulin trial

Kane Biotech launches anti-biofilm shampoo at the Global Pet Expo

Kane Biotech signs first U.S. distribution agreement with King Wholesale

FDA approves Baudax Bio’s ANJESO for pain

VBL Therapeutics launches Phase 2 metastatic colorectal cancer trial

VistaGen reports positive results from Phase 2a major depressive disorder study

Mesoblast moving remestemcel-L into chronic GVHD pivotal trial

Obalon opens second retail treatment center to treat obesity

Hepion’s CRV431 shows potential to impact multiple types of fibrotic disease

General

More